_id
6915fa9dbc934aba376b26d3
Ticker
SLXN
Name
Biomotion Sciences Ordinary Shares
Exchange
NASDAQ
Address
The Goldyne Savad Inst. of Gene Therapy, Jerusalem, Israel, 9112001
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://silexion.com
Description
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Last Close
2.26
Volume
32638
Current Price
2.27
Change
-0.09
Last Updated
2026-01-07T11:56:59.054Z
Image
data:image/webp;base64,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
Ipo Date
2024-08-16T00:00:00.000Z
Market Cap
6597214
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Target Price
9
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
4000
Gross Profit
-4000
Operating Expenses
3288000
Operating Income
-3292000
Interest Expense
4000
Pretax Income
-3262000
Net Income
-3262000
Eps
-2.879951406338012
Dividends Per Share
-
Shares Outstanding
3126642
Income Tax Expense
-
EBITDA
-3258000
Operating Margin
-
Total Other Income Expense Net
30000
Cash
9243000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
11055000
Property Plant Equipment
468000
Total Assets
11614000
Payables
946000
Short Term Debt
174000
Long Term Debt
1540000
Total Liabilities
4637000
Equity
6977000
Bs_currency_symbol
USD
Depreciation
4000
Change In Working Capital
393000
Cash From Operations
-2843000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
8624000
Net Change In Cash
5778000
Cf_currency_symbol
USD
PE
0.006
PB
0.3685156456929913
ROE
-46.753619033968754
ROA
-28.086791802996387
FCF
-2843000
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
8.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
4.5
Net Net Investing Score
3.5
Quality Investing Score
2
Value Investing Score
7
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
4000
Quarters > 0 > income Statement > gross Profit
-4000
Quarters > 0 > income Statement > operating Expenses
3288000
Quarters > 0 > income Statement > operating Income
-3292000
Quarters > 0 > income Statement > interest Expense
4000
Quarters > 0 > income Statement > pretax Income
-3262000
Quarters > 0 > income Statement > net Income
-3262000
Quarters > 0 > income Statement > eps
-2.879951406338012
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1132658
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-3258000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
30000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
9243000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
11055000
Quarters > 0 > balance Sheet > property Plant Equipment
468000
Quarters > 0 > balance Sheet > total Assets
11614000
Quarters > 0 > balance Sheet > payables
946000
Quarters > 0 > balance Sheet > short Term Debt
174000
Quarters > 0 > balance Sheet > long Term Debt
1540000
Quarters > 0 > balance Sheet > total Liabilities
4637000
Quarters > 0 > balance Sheet > equity
6977000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-3262000
Quarters > 0 > cash Flow > depreciation
4000
Quarters > 0 > cash Flow > change In Working Capital
393000
Quarters > 0 > cash Flow > cash From Operations
-2843000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
8624000
Quarters > 0 > cash Flow > net Change In Cash
5778000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-2.879951406338012
Quarters > 0 > ratios > PB
0.3685156456929913
Quarters > 0 > ratios > ROE
-46.753619033968754
Quarters > 0 > ratios > ROA
-28.086791802996387
Quarters > 0 > ratios > FCF
-2843000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
3000
Quarters > 1 > income Statement > gross Profit
-3000
Quarters > 1 > income Statement > operating Expenses
2284000
Quarters > 1 > income Statement > operating Income
-2284000
Quarters > 1 > income Statement > interest Expense
0
Quarters > 1 > income Statement > pretax Income
-2500000
Quarters > 1 > income Statement > net Income
-2503000
Quarters > 1 > income Statement > eps
-4.319069303547918
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
579523
Quarters > 1 > income Statement > income Tax Expense
3000
Quarters > 1 > income Statement > EBITDA
-2497000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-216000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
3466000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
5237000
Quarters > 1 > balance Sheet > property Plant Equipment
502000
Quarters > 1 > balance Sheet > total Assets
5797000
Quarters > 1 > balance Sheet > payables
692000
Quarters > 1 > balance Sheet > short Term Debt
171000
Quarters > 1 > balance Sheet > long Term Debt
3190000
Quarters > 1 > balance Sheet > total Liabilities
5677000
Quarters > 1 > balance Sheet > equity
120000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-2503000
Quarters > 1 > cash Flow > depreciation
3000
Quarters > 1 > cash Flow > change In Working Capital
-273000
Quarters > 1 > cash Flow > cash From Operations
-2507000
Quarters > 1 > cash Flow > capital Expenditures
1000
Quarters > 1 > cash Flow > cash From Investing
-1000
Quarters > 1 > cash Flow > cash From Financing
-195000
Quarters > 1 > cash Flow > net Change In Cash
-2689000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-4.319069303547918
Quarters > 1 > ratios > PB
10.962643416666666
Quarters > 1 > ratios > ROE
-2085.8333333333335
Quarters > 1 > ratios > ROA
-43.17750560634811
Quarters > 1 > ratios > FCF
-2508000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
16
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
4000
Quarters > 2 > income Statement > gross Profit
-4000
Quarters > 2 > income Statement > operating Expenses
1650000
Quarters > 2 > income Statement > operating Income
-1650000
Quarters > 2 > income Statement > interest Expense
9000
Quarters > 2 > income Statement > pretax Income
-1735000
Quarters > 2 > income Statement > net Income
-1735000
Quarters > 2 > income Statement > eps
-0.2559297144724197
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
6779205
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-1722000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-85000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
6152000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
7722000
Quarters > 2 > balance Sheet > property Plant Equipment
534000
Quarters > 2 > balance Sheet > total Assets
8308000
Quarters > 2 > balance Sheet > payables
722000
Quarters > 2 > balance Sheet > short Term Debt
155000
Quarters > 2 > balance Sheet > long Term Debt
2993000
Quarters > 2 > balance Sheet > total Liabilities
5722000
Quarters > 2 > balance Sheet > equity
2586000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-1735000
Quarters > 2 > cash Flow > depreciation
4000
Quarters > 2 > cash Flow > change In Working Capital
-824000
Quarters > 2 > cash Flow > cash From Operations
-2453000
Quarters > 2 > cash Flow > capital Expenditures
6000
Quarters > 2 > cash Flow > cash From Investing
-6000
Quarters > 2 > cash Flow > cash From Financing
7432000
Quarters > 2 > cash Flow > net Change In Cash
4963000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.2559297144724197
Quarters > 2 > ratios > PB
5.950810266821346
Quarters > 2 > ratios > ROE
-67.09203402938901
Quarters > 2 > ratios > ROA
-20.88348579682234
Quarters > 2 > ratios > FCF
-2459000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
23
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
23242
Quarters > 3 > income Statement > operating Income
-23242
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-31272
Quarters > 3 > income Statement > net Income
-31139
Quarters > 3 > income Statement > eps
-0.0033687255606744374
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
9243555
Quarters > 3 > income Statement > income Tax Expense
19
Quarters > 3 > income Statement > EBITDA
-23235.75
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-8030
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
1187000
Quarters > 3 > balance Sheet > short Term Investments
35000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
2250000
Quarters > 3 > balance Sheet > property Plant Equipment
560000
Quarters > 3 > balance Sheet > total Assets
2863000
Quarters > 3 > balance Sheet > payables
929000
Quarters > 3 > balance Sheet > short Term Debt
1162000
Quarters > 3 > balance Sheet > long Term Debt
2961000
Quarters > 3 > balance Sheet > total Liabilities
6852000
Quarters > 3 > balance Sheet > equity
-3989000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-1747000
Quarters > 3 > cash Flow > depreciation
-12000
Quarters > 3 > cash Flow > change In Working Capital
-947000
Quarters > 3 > cash Flow > cash From Operations
-2926000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
2184000
Quarters > 3 > cash Flow > net Change In Cash
-753000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.0033687255606744374
Quarters > 3 > ratios > PB
-5.260182965655553
Quarters > 3 > ratios > ROE
0.7806217097016797
Quarters > 3 > ratios > ROA
-1.087635347537548
Quarters > 3 > ratios > FCF
-2926000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
23
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
25000
Annuals > 0 > income Statement > gross Profit
-25000
Annuals > 0 > income Statement > operating Expenses
12571000
Annuals > 0 > income Statement > operating Income
-12571000
Annuals > 0 > income Statement > interest Expense
52000
Annuals > 0 > income Statement > pretax Income
-16509000
Annuals > 0 > income Statement > net Income
-16443000
Annuals > 0 > income Statement > eps
-2.6357466426008984
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
6238460
Annuals > 0 > income Statement > income Tax Expense
10000
Annuals > 0 > income Statement > EBITDA
-16477000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-3938000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
1187000
Annuals > 0 > balance Sheet > short Term Investments
35000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
2250000
Annuals > 0 > balance Sheet > property Plant Equipment
560000
Annuals > 0 > balance Sheet > total Assets
2863000
Annuals > 0 > balance Sheet > payables
929000
Annuals > 0 > balance Sheet > short Term Debt
1162000
Annuals > 0 > balance Sheet > long Term Debt
2961000
Annuals > 0 > balance Sheet > total Liabilities
6852000
Annuals > 0 > balance Sheet > equity
-3989000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-16519000
Annuals > 0 > cash Flow > depreciation
25000
Annuals > 0 > cash Flow > change In Working Capital
-1580000
Annuals > 0 > cash Flow > cash From Operations
-8396000
Annuals > 0 > cash Flow > capital Expenditures
22000
Annuals > 0 > cash Flow > cash From Investing
-22000
Annuals > 0 > cash Flow > cash From Financing
5104000
Annuals > 0 > cash Flow > net Change In Cash
-3375000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-2.6357466426008984
Annuals > 0 > ratios > PB
-3.299862271245926
Annuals > 0 > ratios > ROE
412.2085735773377
Annuals > 0 > ratios > ROA
-574.3276283618582
Annuals > 0 > ratios > FCF
-8418000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
4681000
Annuals > 1 > income Statement > operating Income
-4681000
Annuals > 1 > income Statement > interest Expense
9000
Annuals > 1 > income Statement > pretax Income
-5076000
Annuals > 1 > income Statement > net Income
-4942000
Annuals > 1 > income Statement > eps
-4.4233213397060664
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
1117260
Annuals > 1 > income Statement > income Tax Expense
32000
Annuals > 1 > income Statement > EBITDA
-4636000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-395000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
4595000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
4979000
Annuals > 1 > balance Sheet > property Plant Equipment
247000
Annuals > 1 > balance Sheet > total Assets
5256000
Annuals > 1 > balance Sheet > payables
319000
Annuals > 1 > balance Sheet > short Term Debt
112000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
17312000
Annuals > 1 > balance Sheet > equity
-15476000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-5108000
Annuals > 1 > cash Flow > depreciation
45000
Annuals > 1 > cash Flow > change In Working Capital
87000
Annuals > 1 > cash Flow > cash From Operations
-4529000
Annuals > 1 > cash Flow > capital Expenditures
12000
Annuals > 1 > cash Flow > cash From Investing
573000
Annuals > 1 > cash Flow > cash From Financing
522000
Annuals > 1 > cash Flow > net Change In Cash
-3664000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-4.4233213397060664
Annuals > 1 > ratios > PB
-0.152327384337038
Annuals > 1 > ratios > ROE
31.933316102352027
Annuals > 1 > ratios > ROA
-94.02587519025876
Annuals > 1 > ratios > FCF
-4541000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
3860000
Annuals > 2 > income Statement > operating Income
-3860000
Annuals > 2 > income Statement > interest Expense
85000
Annuals > 2 > income Statement > pretax Income
-3464000
Annuals > 2 > income Statement > net Income
-3215000
Annuals > 2 > income Statement > eps
-0.1921953733223257
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
16727770
Annuals > 2 > income Statement > income Tax Expense
24000
Annuals > 2 > income Statement > EBITDA
-3803000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
396000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
8259000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
8839000
Annuals > 2 > balance Sheet > property Plant Equipment
464000
Annuals > 2 > balance Sheet > total Assets
9333000
Annuals > 2 > balance Sheet > payables
240000
Annuals > 2 > balance Sheet > short Term Debt
115000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
16412000
Annuals > 2 > balance Sheet > equity
-10665000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-3488000
Annuals > 2 > cash Flow > depreciation
57000
Annuals > 2 > cash Flow > change In Working Capital
239000
Annuals > 2 > cash Flow > cash From Operations
-3335000
Annuals > 2 > cash Flow > capital Expenditures
40000
Annuals > 2 > cash Flow > cash From Investing
-524000
Annuals > 2 > cash Flow > cash From Financing
2752000
Annuals > 2 > cash Flow > net Change In Cash
-1774000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.1921953733223257
Annuals > 2 > ratios > PB
-3.309479109235818
Annuals > 2 > ratios > ROE
30.14533520862635
Annuals > 2 > ratios > ROA
-34.44765884495875
Annuals > 2 > ratios > FCF
-3375000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
31
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
943933
Annuals > 3 > income Statement > operating Income
-943933
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-755218
Annuals > 3 > income Statement > net Income
-755218
Annuals > 3 > income Statement > eps
-0.045755397426926095
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
16505550
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-755000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
188715
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
38944
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
407797
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
115414169
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
508916
Annuals > 3 > balance Sheet > equity
114905252
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-755218
Annuals > 3 > cash Flow > depreciation
-
Annuals > 3 > cash Flow > change In Working Capital
-469675
Annuals > 3 > cash Flow > cash From Operations
-1407236
Annuals > 3 > cash Flow > capital Expenditures
4
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
116400851
Annuals > 3 > cash Flow > net Change In Cash
-12757
Annuals > 3 > cash Flow > currency_symbol
-
Annuals > 3 > ratios > PE
-0.045755397426926095
Annuals > 3 > ratios > PB
0.30309067595970285
Annuals > 3 > ratios > ROE
-0.6572528120820796
Annuals > 3 > ratios > ROA
-0.6543546659336082
Annuals > 3 > ratios > FCF
-1407240
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
41
Valuation > metrics > PE
0.006
Valuation > metrics > PB
0.3685156456929913
Valuation > final Score
90
Valuation > verdict
81.5% Undervalued
Profitability > metrics > ROE
-46.753619033968754
Profitability > metrics > ROA
-29.507010402532792
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6646122975490899
Risk > metrics > Interest Coverage
-823
Risk > final Score
-3244
Risk > verdict
High
Liquidity > metrics > Current Ratio
9.870535714285714
Liquidity > metrics > Quick Ratio
9.870535714285714
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20.49189733178654
Prev Valuations > 2
50
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
17
Prev Risks > 0
-3039
Prev Risks > 1
-715
Prev Risks > 2
18
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
77
Updated At
2026-01-20T22:35:17.839Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-12
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-2.88
Earnings History > 0 > eps Estimate
-3.4
Earnings History > 0 > eps Difference
0.52
Earnings History > 0 > surprise Percent
15.2941
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-07
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-4.3191
Earnings History > 1 > eps Estimate
-0.21
Earnings History > 1 > eps Difference
-4.1091
Earnings History > 1 > surprise Percent
-1956.7143
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-13
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-0.2559
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-18
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-311.4
Earnings History > 3 > eps Estimate
-14.7
Earnings History > 3 > eps Difference
-296.7
Earnings History > 3 > surprise Percent
-2018.3673
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-14
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-274.05
Earnings History > 4 > eps Estimate
-14.85
Earnings History > 4 > eps Difference
-259.2
Earnings History > 4 > surprise Percent
-1745.4545
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-13
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.0286
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-15
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.0517
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2023-12-31
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-10.0188
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-09-30
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
2.0118
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-06-30
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
3.7005
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-03-31
Earnings History > 10 > report Date
2023-03-31
Earnings History > 10 > date
2023-03-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
3.8968
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2022-12-31
Earnings History > 11 > report Date
2023-03-31
Earnings History > 11 > date
2022-12-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
0.03
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-09-30
Earnings History > 12 > report Date
2022-11-14
Earnings History > 12 > date
2022-09-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
0.02
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2022-06-30
Earnings History > 13 > report Date
2022-08-15
Earnings History > 13 > date
2022-06-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
0.388
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-03-31
Earnings History > 14 > report Date
2022-05-23
Earnings History > 14 > date
2022-03-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.02
Earnings History > 14 > eps Estimate
-
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2021-12-31
Earnings History > 15 > report Date
2022-03-31
Earnings History > 15 > date
2021-12-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.02
Earnings History > 15 > eps Estimate
-
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2021-09-30
Earnings History > 16 > report Date
2021-11-09
Earnings History > 16 > date
2021-09-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.02
Earnings History > 16 > eps Estimate
-
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-06-30
Earnings History > 17 > report Date
2021-08-16
Earnings History > 17 > date
2021-06-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.01
Earnings History > 17 > eps Estimate
-
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-03-31
Earnings History > 18 > report Date
2021-05-25
Earnings History > 18 > date
2021-03-31
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
-
Earnings History > 18 > eps Actual
-0.01
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
-0.01
Earnings History > 18 > surprise Percent
-
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASilexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - marketscreener.com
1/21/2026
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit marketscreener.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$9
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Biomotion Sciences Ordinary Shares
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-2.88
EPS Estimate
-3.4
EPS Difference
0.52
Surprise Percent
15.2941%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.